Targeted Oncology

, Volume 14, Issue 5, pp 619–626 | Cite as

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion

  • Silvia La Monica
  • Roberta Minari
  • Daniele Cretella
  • Mara Bonelli
  • Claudia Fumarola
  • Andrea Cavazzoni
  • Maricla Galetti
  • Graziana Digiacomo
  • Federica Riccardi
  • Pier Giorgio Petronini
  • Marcello TiseoEmail author
  • Roberta Alfieri
Short Communication



Osimertinib is a new third-generation, epidermal growth factor receptor-tyrosine kinase inhibitor highly selective for the epidermal growth factor receptor with both activating and T790M mutations. A recent phase III trial showed a statistically significant progression-free survival benefit with osimertinib vs. gefitinib or erlotinib as first-line treatment for EGFR-mutated non-small cell lung cancer, and preliminary data are available on resistance mechanisms to first-line osimertinib therapy.


The objective of this study was to examine potential in vitro mechanisms of acquired resistance to osimertinib in a cell model carrying an EGFR exon 19 deletion.


PC9 cells were cultured in the presence of increasing concentrations of osimertinib (ranging from 10 to 500 nM) to generate resistant cells. Three clones resistant to osimertinib (half maximal inhibitory concentration > 1 μM) were isolated, genotyped by next-generation sequencing and tested for drug sensitivity. Cell proliferation and migration, cell death, and signaling transduction pathways were analyzed.


Our study revealed that all the three resistant clones developed acquired resistance via the BRAF G469A mutation maintaining a constitutive activation of the ERK pathway. Stable transfection of PC9 and HCC827 cells with a plasmid containing BRAF G469A rendered the cells resistant to osimertinib. Treatment with selumetinib and trametinib, but not dabrafenib, restored the sensitivity to osimertinib and enhanced cell death in the resistant clones with the BRAF G469A mutation.


Our in vitro studies revealed the BRAF G469A-activating mutation as a potential mechanism of acquired resistance to first-line osimertinib treatment, and provide a strategy of intervention to overcome this mechanism of resistance.


Compliance with Ethical Standards


This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan Grant IG2017-20074 (P.I. Marcello Tiseo). AstraZeneca provided a research grant to Marcello Tiseo.

Conflict of Interest

Marcello Tiseo has been on advisory boards and received speakers’ fees for Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. Marcello Tiseo has received research grants from Astra-Zeneca and Boehringer Ingelheim. Silvia La Monica, Roberta Minari, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Maricla Galetti, Graziana Digiacomo, Federica Riccardi, Pier Giorgio Petronini, and Roberta Alfieri have no conflicts of interest that are directly relevant to the content of this article.

Supplementary material

11523_2019_669_MOESM1_ESM.pdf (120 kb)
Supplementary material 1 (PDF 120 kb)


  1. 1.
    Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):863–70. Scholar
  2. 2.
    Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11(8):473–81. Scholar
  3. 3.
    Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40. Scholar
  4. 4.
    Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2016;5(6):695–708. Scholar
  5. 5.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. Scholar
  6. 6.
    Ramalingam SS, Rukazenkov Y, Todd A, Markovets A, Chmielecki J, Barrett JC, et al. LBA50. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018. Scholar
  7. 7.
    Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol. 2015;10(5):768–77. Scholar
  8. 8.
    Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–51. Scholar
  9. 9.
    Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev. 2018;66:82–94. Scholar
  10. 10.
    Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012;109(31):E2127–33. Scholar
  11. 11.
    Minari R, Bordi P, La Monica S, Squadrilli A, Leonetti A, Bottarelli L, et al. Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in a patient with EGFR-mutated NSCLC. J Thorac Oncol. 2018;13(6):e89–91. Scholar
  12. 12.
    Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Chih-Hsin Yang J. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12(3):567–72. Scholar
  13. 13.
    Bearz A, De Carlo E, Doliana R, Schiappacassi M. Acquired BRAF V600E mutation as resistant mechanism after treatment with third-generation EGFR tyrosine kinase inhibitor. J Thorac Oncol. 2017;12(11):e181–2. Scholar
  14. 14.
    La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, et al. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol. 2009;78(5):460–8. Scholar
  15. 15.
    Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ. 2005;12(10):1344–57. Scholar
  16. 16.
    La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, et al. Gefitinib inhibits invasive phenotype and epithelial–mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One. 2013;8(10):e78656. Scholar
  17. 17.
    Cavazzoni A, Alfieri RR, Carmi C, Zuliani V, Galetti M, Fumarola C, et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther. 2008;7(2):361–70. Scholar
  18. 18.
    Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2(3):261–74. Scholar
  19. 19.
    Oxnard G, Hu Y, Mileham K, Tracy P, Feeney N, Sholl L, et al. OA 09.02 Osimertinib resistance mediated by loss of EGFR T790M is associated with early resistance and competing resistance mechanisms. J Thorac Oncol. 2017;12(11):S1767–8. Scholar
  20. 20.
    Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–34. Scholar
  21. 21.
    Ku BM, Choi MK, Sun JM, Lee SH, Ahn JS, Park K, et al. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. PLoS One. 2018;13(4):e0194730. Scholar
  22. 22.
    Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75(12):2489–500. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Silvia La Monica
    • 1
  • Roberta Minari
    • 2
  • Daniele Cretella
    • 1
  • Mara Bonelli
    • 1
  • Claudia Fumarola
    • 1
  • Andrea Cavazzoni
    • 1
  • Maricla Galetti
    • 3
    • 4
  • Graziana Digiacomo
    • 1
  • Federica Riccardi
    • 5
  • Pier Giorgio Petronini
    • 1
  • Marcello Tiseo
    • 1
    • 2
    Email author
  • Roberta Alfieri
    • 1
  1. 1.Department of Medicine and SurgeryUniversity of ParmaParmaItaly
  2. 2.Medical Oncology UnitUniversity Hospital of ParmaParmaItaly
  3. 3.Italian Workers’ Compensation Authority (INAIL) Research CenterParmaItaly
  4. 4.Center of Excellence for Toxicological Research (CERT)University of ParmaParmaItaly
  5. 5.Regional Reference Centre for Inherited Bleeding DisordersUniversity Hospital of ParmaParmaItaly

Personalised recommendations